Keros Therapeutics(US:KROS)2026-03-04 21:04Financial Performance - The company reported a net income of $87.0 million for the year ended December 31, 2025, compared to a net loss of $187.4 million for the year ended December 31, 2024[570]. - Total revenue for the year ended December 31, 2025, was $244.1 million, a significant increase from $3.6 million in 2024[598]. - License revenue from the Takeda Agreement was $205.4 million for 2025, compared to $3.0 million in 2024[599]. - The company recognized $24.9 million in dividend income for 2025, compared to $23.5 million in 2024[603]. - The income tax provision for 2025 was $4.9 million, up from $0.3 million in 2024, due to taxable income from the Takeda Agreement[604]. - The company reported a net income of $87.0 million for the year ended December 31, 2025, compared to a net loss of $187.4 million for the year ended December 31, 2024[606]. - As of December 31, 2025, the company had an accumulated deficit of $481.8 million, down from $568.8 million as of December 31, 2024[606]. Cash and Liquidity - As of December 31, 2025, the company had cash and cash equivalents of $287.4 million, expected to fund operations into the first half of 2028[574]. - Cash and cash equivalents as of December 31, 2025, were $287.4 million, expected to fund liquidity requirements into the first half of 2028[611]. - Net cash provided by operating activities was $107.5 million for the year ended December 31, 2025, driven by a net income and non-cash charges[614]. - Net cash used in financing activities was $378.5 million for the year ended December 31, 2025, primarily due to share repurchases totaling $375.0 million[618]. - The company plans to distribute 25% of any net cash proceeds from the Takeda Agreement to stockholders by December 31, 2028[622]. Share Transactions - The company has sold a total of 4,290,096 shares under the ATM Sales Agreement for aggregate net proceeds of approximately $228.6 million[565]. - In January 2024, the company closed a public offering, issuing 4,025,000 shares at a price of $40.00 per share, resulting in net proceeds of approximately $151.1 million[566]. - The company accepted for purchase 10,950,165 shares at a price of $17.75 per share during the Tender Offer, totaling approximately $194.4 million[569]. - The company completed a Tender Offer in November 2025, purchasing 10,950,165 shares at a price of $17.75 per share, totaling approximately $194.4 million[610]. Research and Development - The company has incurred recurring operating losses each fiscal year since its inception in 2015, with an accumulated deficit of $481.8 million as of December 31, 2025[570]. - The company has not generated any revenue from product sales as none of its product candidates have been approved for commercialization[563]. - The company expects to continue to incur operating losses and negative cash flows as it advances its product candidates through clinical development[572]. - Research and development expenses decreased to $129.6 million in 2025 from $173.6 million in 2024, a reduction of $44.0 million[600]. - Research and development incentive income from the Australian government was $1.2 million in 2024, but no income was recognized in 2025[603]. - The company is entitled to receive up to $1.1 billion in additional milestone payments under the Takeda Agreement, including $80.0 million for development milestones and $280.0 million for commercial milestones[585]. Agreements and Contracts - The company entered into a licensing agreement with Takeda Pharmaceuticals for the development and commercialization of elritercept, effective January 16, 2025[562]. - The company received a $200.0 million upfront payment from Takeda in February 2025, along with a $10.0 million milestone payment in August 2025[585]. - The company is entitled to receive up to $23.5 million in development milestone payments and $144.0 million upon achieving specified net sales thresholds under the Hansoh Agreement[580]. Operating Expenses - General and administrative expenses increased to $46.8 million in 2025 from $40.8 million in 2024, an increase of $6.1 million[602]. Accounting Policies - The company recognizes revenue based on the transfer of control for goods or services, with distinct licenses recognized when transferred to the customer[630]. - Payments from customers are recorded as deferred revenue until obligations are satisfied, with accounts receivable recognized when the right to consideration is unconditional[631]. - The company estimates accrued research and development expenses based on known facts and circumstances, with adjustments made if actual performance varies from estimates[632]. - Stock-based compensation is recognized at fair value, with costs allocated over the vesting period or based on performance conditions using the Black-Scholes option-pricing model[633]. - The company is classified as a "smaller reporting company" and is not required to provide certain market risk disclosures[636].